Iran is facing new pressure on its pharmaceutical sector as officials warn about slower imports of medicine ingredients. Drug supply delays have increased concerns across the healthcare industry. Authorities say maritime restrictions and higher transport expenses continue to disrupt supply chains.
Mehdi Pirsalehi, head of Iran Food and Drug Administration, said some pharmaceutical ingredients and medicines now arrive later than expected. He explained that shipping barriers and national restrictions have complicated import operations in recent months.
Pirsalehi said officials are working with Ministry of Roads and Urban Development of Iran to secure alternative transport routes. The government aims to protect medicine production and prevent shortages across the domestic market.
The official also pointed to growing economic pressure on major industries. He said damage linked to the recent conflict affected petrochemical and steel production. Rising logistics expenses also pushed pharmaceutical companies to review product pricing.
Iran’s pharmaceutical sector depends heavily on imported raw materials. Many local producers require foreign chemical compounds and packaging materials to maintain production levels. Shipping disruptions therefore create immediate pressure on factories and distributors.
Industry analysts say transportation costs have climbed sharply since the conflict began earlier this year. Insurance rates for cargo shipments also increased across several regional trade corridors. These changes placed additional financial pressure on suppliers and importers.
The conflict between the United States, Israel, and Iran intensified regional instability during recent months. Several Iranian industrial facilities faced direct and indirect damage during military operations. Some pharmaceutical infrastructure reportedly suffered disruptions during that period.
Health sector experts warn that longer import delays could affect hospitals and pharmacies if conditions continue. Drug supply delays may also influence treatment access for patients with chronic illnesses. Companies are now attempting to secure larger inventories to reduce future risks.
Economic observers believe the pharmaceutical industry remains highly sensitive to international transport disruptions. Many firms already face currency volatility and rising operational expenses. Delayed shipments now add another layer of uncertainty for manufacturers.
Government agencies have recently expanded coordination efforts with transport authorities and customs officials. These measures aim to accelerate cargo clearance and protect medical supply chains. Officials also want to prevent panic buying in local markets.
Pharmaceutical producers continue to monitor raw material inventories closely. Some companies have reportedly adjusted production schedules because of uncertain delivery timelines. Business groups are also requesting additional financial support from state institutions.
Drug supply delays have become a major issue for both healthcare providers and industry executives. Market participants say stable transportation routes remain critical for long-term medicine security. The government now faces growing pressure to maintain supply stability while controlling rising costs.
Analysts expect Iranian authorities to continue expanding alternative trade routes during coming months. Importers may also seek new regional suppliers to reduce dependency on vulnerable shipping channels. Drug supply delays will likely remain a key concern unless regional tensions ease and transport conditions improve.